Shanghai RAAS Blood Products

Historical price data

Shanghai RAAS Blood Products is a critical enterprise in China's national biopharmaceutical strategy, focusing on ensuring the supply and safety of plasma-derived therapies. The company operates numerous plasma collection stations and has a vertically integrated manufacturing platform, positioning it as a dominant force in a market with significant barriers to entry. Its strategic direction involves expanding its plasma fractionation capacity, advancing its recombinant protein pipeline, and leveraging its scale to meet growing domestic demand for essential blood products.

Large-scale plasma fractionation and purification technology for isolating therapeutic proteins from human plasma, complemented by developing recombinant protein expression capabilities.

Operates in an oligopolistic market with primary competitors being Hualan Biological, China Biologic (Tiancheng), and Tiantan Biological. Differentiation is achieved through scale of plasma collection, vertical integration, fractionation capacity, and a broad product portfolio.